<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Alamar Biosciences, Inc.</title>
    <link>https://www.biospace.com/employer/1846067/alamar-biosciences-inc</link>
    <description>Alamar Biosciences, Inc.</description>
    <language>en-US</language>
    <lastBuildDate>Tue, 15 Feb 2022 16:12:07 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/1846067/alamar-biosciences-inc.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Three Big Antibody Research Collabs Hit the Wire</title>
      <link>https://www.biospace.com/three-big-collabs-for-autoimmune-disease</link>
      <dc:creator>Hannah Chudleigh</dc:creator>
      <description>Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.</description>
      <pubDate>Tue, 15 Feb 2022 16:12:07 GMT</pubDate>
      <guid>https://www.biospace.com/three-big-collabs-for-autoimmune-disease</guid>
    </item>
    <item>
      <title>Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market</title>
      <link>https://www.biospace.com/alamar-biosciences-completes-80m-series-b-fundraising-to-bring-unprecedented-performance-to-the-proteomics-market</link>
      <description>Alamar Biosciences, Inc. announced today that it has closed its $80 million Series B financing round, bringing its total funding to $110 million .</description>
      <pubDate>Wed, 08 Sep 2021 12:36:13 GMT</pubDate>
      <guid>https://www.biospace.com/alamar-biosciences-completes-80m-series-b-fundraising-to-bring-unprecedented-performance-to-the-proteomics-market</guid>
    </item>
    <item>
      <title>Alamar Biosciences partners with Abcam to drive understanding of the human proteome</title>
      <link>https://www.biospace.com/alamar-biosciences-partners-with-abcam-to-drive-understanding-of-the-human-proteome</link>
      <description>Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform.</description>
      <pubDate>Tue, 04 Jan 2022 11:36:07 GMT</pubDate>
      <guid>https://www.biospace.com/alamar-biosciences-partners-with-abcam-to-drive-understanding-of-the-human-proteome</guid>
    </item>
    <item>
      <title>SciNeuro Pharmaceuticals and Alamar Biosciences Collaborate to Discover Novel Therapeutic Antibodies for CNS Diseases</title>
      <link>https://www.biospace.com/scineuro-pharmaceuticals-and-alamar-biosciences-collaborate-to-discover-novel-therapeutic-antibodies-for-cns-diseases</link>
      <description>Alamar Biosciences and SciNeuro Pharmaceuticals announced a multi-program collaboration and license agreement to discover and develop novel therapeutic antibodies for targets selected by SciNeuro within the field of neurological diseases, based on Alamar's Attobody platform.</description>
      <pubDate>Tue, 15 Feb 2022 12:06:18 GMT</pubDate>
      <guid>https://www.biospace.com/scineuro-pharmaceuticals-and-alamar-biosciences-collaborate-to-discover-novel-therapeutic-antibodies-for-cns-diseases</guid>
    </item>
    <item>
      <title>Mologic and Alamar Biosciences collaborate to develop a next generation COVID-19 antigen test</title>
      <link>https://www.biospace.com/mologic-and-alamar-biosciences-collaborate-to-develop-a-next-generation-covid-19-antigen-test</link>
      <description>Alamar Biosciences (Alamar), and Mologic, Ltd. (Mologic), today announced a collaboration to utilize Alamar's novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic's future COVID-19 RDTs.</description>
      <pubDate>Wed, 04 May 2022 13:16:08 GMT</pubDate>
      <guid>https://www.biospace.com/mologic-and-alamar-biosciences-collaborate-to-develop-a-next-generation-covid-19-antigen-test</guid>
    </item>
    <item>
      <title>Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability</title>
      <link>https://www.biospace.com/alamar-biosciences-unveils-novel-proteomics-platform-with-best-in-class-sensitivity-and-high-multiplexing-capability</link>
      <description>Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the unveiling of its technology platform NULISA™, a novel automated ultrasensitive and highly multiplexed proteomics technology for liquid biopsy.</description>
      <pubDate>Wed, 12 Apr 2023 13:06:11 GMT</pubDate>
      <guid>https://www.biospace.com/alamar-biosciences-unveils-novel-proteomics-platform-with-best-in-class-sensitivity-and-high-multiplexing-capability</guid>
    </item>
    <item>
      <title>Alamar Biosciences Announces Seminal Publication in Nature Communications Demonstrating Superior Performance of the NULISA™ Platform</title>
      <link>https://www.biospace.com/alamar-biosciences-announces-seminal-publication-in-nature-communications-demonstrating-superior-performance-of-the-nulisa-platform</link>
      <description>Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the first publication of a paper in Nature Communications on the development and validation of its NULISA technology.</description>
      <pubDate>Thu, 09 Nov 2023 18:46:03 GMT</pubDate>
      <guid>https://www.biospace.com/alamar-biosciences-announces-seminal-publication-in-nature-communications-demonstrating-superior-performance-of-the-nulisa-platform</guid>
    </item>
    <item>
      <title>Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids</title>
      <link>https://www.biospace.com/alamar-biosciences-announces-commercial-launch-of-the-argo-ht-system-and-the-nulisaseq-inflammation-panel-250-for-ultra-high-sensitivity-protein-analysis-in-biofluids</link>
      <description>Alamar Biosciences announced the commercial launch of the ARGO HT System for push-button, high sensitivity analysis of proteins in biofluids and the NULISAseq Inflammation Panel 250 for deep profiling of immune response.</description>
      <pubDate>Thu, 04 Jan 2024 13:36:11 GMT</pubDate>
      <guid>https://www.biospace.com/alamar-biosciences-announces-commercial-launch-of-the-argo-ht-system-and-the-nulisaseq-inflammation-panel-250-for-ultra-high-sensitivity-protein-analysis-in-biofluids</guid>
    </item>
    <item>
      <title>Alamar Biosciences Raises $128 Million in Oversubscribed Series C Financing to Accelerate Commercialization of its Proteomics Platform</title>
      <link>https://www.biospace.com/alamar-biosciences-raises-128-million-in-oversubscribed-series-c-financing-to-accelerate-commercialization-of-its-proteomics-platform</link>
      <description>Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the first close of $100 million in Series C financing with the second close of an additional $28 million expected to happen within the next 30 days.</description>
      <pubDate>Mon, 26 Feb 2024 21:16:05 GMT</pubDate>
      <guid>https://www.biospace.com/alamar-biosciences-raises-128-million-in-oversubscribed-series-c-financing-to-accelerate-commercialization-of-its-proteomics-platform</guid>
    </item>
    <item>
      <title>Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer's Disease Research</title>
      <link>https://www.biospace.com/alamar-biosciences-and-alzpath-inc-announce-strategic-supply-agreement-for-ptau217-antibody-to-advance-alzheimer-s-disease-research</link>
      <description>Alamar Biosciences is pleased to announce a strategic supply agreement with ALZpath, a leading developer of diagnostic solutions in Alzheimer's disease and related dementias.</description>
      <pubDate>Thu, 29 Feb 2024 14:16:05 GMT</pubDate>
      <guid>https://www.biospace.com/alamar-biosciences-and-alzpath-inc-announce-strategic-supply-agreement-for-ptau217-antibody-to-advance-alzheimer-s-disease-research</guid>
    </item>
  </channel>
</rss>
